Therapy Areas: Devices
SonaCare Releases 5-Year Study Results of Focused Ultrasound Therapy for Prostate Cancer
11 July 2018 - - Charlotte, North Carolina-based high intensity focused ultrasound (HIFU) technologies specialist SonaCare Medical has reported 5-year outcomes from a multicenter study following focal therapy treatment with its Sonablate technology of 625 medium to high-risk clinically significant nonmetastatic prostate cancer patients, the company said.
With a median five-year follow-up, failure free survival at one, three, and five years was 99%, 92%, and 88% respectively, equivalent to that achieved with surgery. Metastasis-free, cancer-specific, and overall survival at five years was 98%, 100%, and 99% respectively.
The study additionally reports that 98% of men maintained pad-free urinary continence after their procedure and 85% maintained erectile function, both material improvements over that seen with surgery and radiation therapy.
The study concluded that failure free survival with HIFU can be equivalent to that of surgery but with a side effect profile far more beneficial to the patient's quality of life post-procedure.
Sonablate has 510(K) clearance in the US and is indicated for the transrectal high intensity focused ultrasound ablation of prostatic tissue.
SonaCare Medical is committed to developing focused ultrasound related technologies that support precise and innovative procedures for the treatment of a range of medical conditions. SonaCare Medical, with its subsidiary Focus Surgery, Inc., designs and manufactures medical devices.
Login
Username:

Password: